- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07444372
Initié la thérapie CPAP chez les patients atteints d'apnée obstructive du sommeil après une ablation de la fibrillation auriculaire (STOP-AFib)
Début de la thérapie CPAP chez les patients atteints d'apnée obstructive du sommeil après une ablation de fibrillation auriculaire : un essai clinique multicentrique, ouvert et randomisé
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.
This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.
Participants will:
- Be randomly assigned to either the CPAP group or the usual care group.
- If in the CPAP group, use a CPAP device for 12 months.
- Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
- Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.
After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.
Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.
The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jiang Xie, Professor
- Numéro de téléphone: +86 64456360
- E-mail: frank782008@aliyun.com
Lieux d'étude
-
-
-
Tianjin, Chine
- Pas encore de recrutement
- Tianjin Medical University Second Hospital
-
Chercheur principal:
- Xiaoyun Zhao, Professor
-
Contact:
- Xiaoyun Zhao, Professor
- Numéro de téléphone: +86-022-88326681
- E-mail: zxydoctor@163.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100029
- Recrutement
- Beijing Anzhen Hospital
-
Contact:
- Jiang Xie, Professor
- Numéro de téléphone: +86 64456360
- E-mail: frank782008@aliyun.com
-
Chercheur principal:
- Jiang Xie, Professor
-
Chercheur principal:
- Shaoping Nie, Professor
-
Chercheur principal:
- Deyong Long, Professor
-
Beijing, Beijing Municipality, Chine, 100730
- Pas encore de recrutement
- Beijing Hospital
-
Contact:
- Wei Gong, Professor
- Numéro de téléphone: +86 85132266
- E-mail: gongwei5180@bjhmoh.cn
-
Chercheur principal:
- Wei Gong, Professor
-
Beijing, Beijing Municipality, Chine, 102206
- Pas encore de recrutement
- Peking University International Hospital
-
Contact:
- Yanwen Jiang, Professor
- Numéro de téléphone: +86 01069006163
- E-mail: jiangyanwen@pkuih.edu.cn
-
Chercheur principal:
- Yanwen Jiang, Professor
-
Beijing, Beijing Municipality, Chine, 100020
- Pas encore de recrutement
- Beijing Chaoyang Hospital, Capital Medical University
-
Contact:
- Zhiling Zhao, Professor
- Numéro de téléphone: +86-10-85231000
- E-mail: cysleep@163.com
-
Chercheur principal:
- Zhiling Zhao, Professor
-
Beijing, Beijing Municipality, Chine, 100035
- Pas encore de recrutement
- Beijing Jishuitan Hospital
-
Contact:
- Yang Cheng, Professor
- Numéro de téléphone: +86 01058516688
- E-mail: hengyang0323@outlook.com
-
Chercheur principal:
- Yang Cheng, Professor
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350001
- Pas encore de recrutement
- Fujian Medical University Union Hospital
-
Contact:
- Xiangqi Chen, Professor
- Numéro de téléphone: +86-591-83357896
- E-mail: chxqq2003@126.com
-
Chercheur principal:
- Xiangqi Chen, Professor
-
Fuzhou, Fujian, Chine, 350004
- Pas encore de recrutement
- First Affiliated Hospital of Fujian Medical University
-
Contact:
- Ningfang Lian, Professor
- Numéro de téléphone: +86 059187981698
- E-mail: 1533532863@qq.com
-
Chercheur principal:
- Ningfang Lian, Professor
-
Zhangzhou, Fujian, Chine, 363000
- Pas encore de recrutement
- Zhangzhou Hospital of Fujian Province
-
Contact:
- Li Lin, Professor
- Numéro de téléphone: +86-596-2082000
- E-mail: linlid222@163.com
-
Chercheur principal:
- Li Lin, Professor
-
-
Guangxi
-
Nanning, Guangxi, Chine, 530021
- Pas encore de recrutement
- People's Hospital of Guangxi Zhuang Autonomous Region
-
Contact:
- Mingming Zhao, Professor
- Numéro de téléphone: +86-771-2186076
- E-mail: topabigale@163.com
-
Chercheur principal:
- Mingming Zhao, Professor
-
-
Hebei
-
Langfang, Hebei, Chine, 065000
- Pas encore de recrutement
- Langfang People's Hospital
-
Contact:
- Zengming Xue, Professor
- Numéro de téléphone: +86 03162369665
- E-mail: xuezengming@163.com
-
Chercheur principal:
- Zengming Xue, Professor
-
Shijiazhuang, Hebei, Chine, 050000
- Recrutement
- Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
-
Contact:
- Linyi Huang, Professor
- Numéro de téléphone: +86-0311-85837801
- E-mail: 496777551@qq.com
-
Chercheur principal:
- Linyi Huang, Professor
-
Xingtai, Hebei, Chine, 055250
- Recrutement
- The Ninth Hospital of Xingtai
-
Contact:
- Zhanwei Liu, Professor
- Numéro de téléphone: +86-0319-4321827
- E-mail: liuzhanweidf@sina.com
-
Chercheur principal:
- Zhanwei Liu, Professor
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150086
- Pas encore de recrutement
- Second Affiliated Hospital of Harbin Medical University
-
Contact:
- Wei Meng, Professor
- Numéro de téléphone: +86 045186296870
- E-mail: mengweixq@163.com
-
Chercheur principal:
- Wei Meng, Professor
-
-
Henan
-
Shangqiu, Henan, Chine
- Pas encore de recrutement
- Shangqiu First People's Hospital
-
Contact:
- Renshan Niu, Professor
- Numéro de téléphone: +86-0370-3255630
- E-mail: niurenshan1965@163.com
-
Chercheur principal:
- Renshan Niu, Professor
-
Zhengzhou, Henan, Chine, 450052
- Pas encore de recrutement
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Gangqiong Liu
- Numéro de téléphone: +86-371-66913114
- E-mail: doctorliu61352@163.com
-
Chercheur principal:
- Gangqiong Liu, Professor
-
-
Hubei
-
Wuhan, Hubei, Chine, 430014
- Pas encore de recrutement
- Wuhan No. 1 Hospital
-
Contact:
- Zhihua Yu, Professor
- Numéro de téléphone: +86 02785332144
- E-mail: whyu027@163.com
-
Chercheur principal:
- Zhihua Yu, Professor
-
Wuhan, Hubei, Chine, 430056
- Pas encore de recrutement
- Wuhan Asia General Hospital
-
Contact:
- Ning Man, Professor
- Numéro de téléphone: +86-027-84788999
- E-mail: Mannyl75@126.com
-
Chercheur principal:
- Ning Man, Professor
-
-
Hunan
-
Changsha, Hunan, Chine, 410011
- Pas encore de recrutement
- The Second Xiangya Hospital of Central South University
-
Contact:
- Ruoyun Ouyang, Professor
- Numéro de téléphone: +86-731-85295888
- E-mail: ouyangruoyun@csu.edu.cn
-
Chercheur principal:
- Ruoyun Ouyang, Professor
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210029
- Pas encore de recrutement
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Ning Ding, Professor
- Numéro de téléphone: +86 02568307346
- E-mail: dingning@njmu.edu.cn
-
Chercheur principal:
- Ning Ding, Professor
-
-
Jilin
-
Changchun, Jilin, Chine, 130021
- Pas encore de recrutement
- The First Hospital of Jilin University
-
Contact:
- Haibo Yuan, Professor
- Numéro de téléphone: +86-431-88782222
- E-mail: hyuan@jlu.edu.cn
-
Chercheur principal:
- Haibo Yuan, Professor
-
-
Liaoning
-
Dalian, Liaoning, Chine, 116011
- Pas encore de recrutement
- First Affiliated Hospital of Dalian Medical University
-
Contact:
- Haiying Tang, Professor
- Numéro de téléphone: +86 0411836359632561
- E-mail: doctortanghy@163.com
-
Chercheur principal:
- Haiying Tang, Professor
-
Shenyang, Liaoning, Chine, 110004
- Pas encore de recrutement
- Shengjing Hospital of China Medical University
-
Contact:
- Li Xiao, Professor
- Numéro de téléphone: +86-24-96615
- E-mail: xiaolisy@163.com
-
Chercheur principal:
- Li Xiao, Professor
-
Shenyang, Liaoning, Chine, 110001
- Pas encore de recrutement
- First Affiliated Hospital of China Medical University
-
Contact:
- Wenyang Li, Professor
- Numéro de téléphone: +86 83282530
- E-mail: 20122043@cmu.edu.cn
-
Chercheur principal:
- Wenyang Li, Professor
-
-
Shandong
-
Dongying, Shandong, Chine, 257034
- Pas encore de recrutement
- Shengli Oilfield Central Hospital
-
Contact:
- Xiangfei Liu, Professor
- Numéro de téléphone: +86-546-8551222
- E-mail: zhaoyang20023903@126.com
-
Chercheur principal:
- Xiangfei Liu, Professor
-
Linyi, Shandong, Chine, 276003
- Pas encore de recrutement
- Linyi People's Hospital
-
Contact:
- Li Wei, Professor
- Numéro de téléphone: +86-539-8216261
- E-mail: weilineu@163.com
-
Chercheur principal:
- Li Wei, Professor
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030001
- Pas encore de recrutement
- Second Hospital of Shanxi Medical University
-
Contact:
- Xiaoling Gao, Professor
- Numéro de téléphone: +86 03513362858
- E-mail: yihexiyuan@qq.com
-
Chercheur principal:
- Xiaoling Gao, Professor
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300222
- Pas encore de recrutement
- Tianjin Chest Hospital
-
Contact:
- Fang Zhao, Professor
- Numéro de téléphone: +86-22-88185111
- E-mail: zfangdoctortjxkyy@163.com
-
Chercheur principal:
- Fang Zhao, Professor
-
-
Yunnan
-
Kunming, Yunnan, Chine
- Pas encore de recrutement
- Yan'an Hospital of Kunming City
-
Contact:
- Xia Jiang, Professor
- Numéro de téléphone: +86-0871-63211073
- E-mail: 378972370@qq.com
-
Chercheur principal:
- Xia Jiang, Professor
-
-
Zhejiang
-
Ningbo, Zhejiang, Chine, 315010
- Pas encore de recrutement
- First Affiliated Hospital of Ningbo University
-
Contact:
- Maoqing Tong, Professor
- Numéro de téléphone: +86 57487085588
- E-mail: ganbaursy@163.com
-
Chercheur principal:
- Maoqing Tong, Professor
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Patients must meet all of the following conditions to be eligible for the study:
- Age 18-75 years.
- Patients with persistent AF who received catheter ablation for the first time.
- Diagnosed with OSA.
- Able to tolerate CPAP therapy.
- Capable of understanding and complying with the study protocol.
- Willing to sign the informed consent form.
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded from the study:
- Secondary AF.
- Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
- Left ventricular ejection fraction < 30%.
- Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
- Pregnant or breastfeeding women.
- History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
- History of stroke or transient ischemic attack within 6 months prior to screening.
- Perioperative complications related to the ablation procedure occurring prior to randomization.
- Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
- Life expectancy < 1 year.
- Central sleep apnea.
- Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia.
- Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
- Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
- Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
- Current participation in other drug or device trials.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CPAP Group
Usual care combined with CPAP therapy. |
Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days. Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives. |
|
Comparateur actif: Usual Care Group
Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device. |
Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of freedom from atrial arrhythmia recurrence.
Délai: Within 12 months
|
Recurrence is defined as a composite of:
|
Within 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence de toute arythmie auriculaire documentée (FA/AFL/TA) durant ≥ 30 secondes.
Délai: Dans les 12 mois (après une période de silence de 3 mois).
|
Dans les 12 mois (après une période de silence de 3 mois).
|
|
|
Incidence de FA documentée durant ≥30 secondes.
Délai: Dans un délai de 12 mois (après une période d'exclusion de 3 mois).
|
Dans un délai de 12 mois (après une période d'exclusion de 3 mois).
|
|
|
Incidence d’un AT documenté d’une durée ≥ 30 secondes.
Délai: Dans les 12 mois (après une période de 3 mois de flou thérapeutique).
|
Dans les 12 mois (après une période de 3 mois de flou thérapeutique).
|
|
|
Incidence de FA documentée d'une durée ≥ 30 secondes.
Délai: Dans les 12 mois (après une période de carence de 3 mois).
|
Dans les 12 mois (après une période de carence de 3 mois).
|
|
|
Proportion de patients utilisant des médicaments antiarythmiques de classe I ou III.
Délai: Dans les 12 mois (après une période de silence de 3 mois).
|
Dans les 12 mois (après une période de silence de 3 mois).
|
|
|
Proportion de patients subissant une cardioversion.
Délai: Dans les 12 mois (après une période de carence de 3 mois).
|
Dans les 12 mois (après une période de carence de 3 mois).
|
|
|
Proportion de patients subissant une nouvelle ablation par cathéter.
Délai: Dans les 12 mois.
|
Dans les 12 mois.
|
|
|
Charge en FA
Délai: Dans les 12 mois.
|
Dans les 12 mois.
|
|
|
Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.
Délai: Baseline, Month 12.
|
Scores range from 0 to 100, where higher scores indicate a better quality of life. |
Baseline, Month 12.
|
|
Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Délai: Baseline, Month 12.
|
Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression. |
Baseline, Month 12.
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: A randomized controlled trial. Int J Cardiol. 2019 Mar 1;278:133-136. doi: 10.1016/j.ijcard.2018.11.100. Epub 2018 Nov 20.
- Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21.
- Dretzke J, Chuchu N, Agarwal R, Herd C, Chua W, Fabritz L, Bayliss S, Kotecha D, Deeks JJ, Kirchhof P, Takwoingi Y. Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace. 2020 May 1;22(5):748-760. doi: 10.1093/europace/euaa041.
- Sanchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Sanchez-de-la-Torre A, Moncusi-Moix A, Torres G, Loffler K, Woodman R, Adams R, Labarca G, Dreyse J, Eulenburg C, Thunstrom E, Glantz H, Peker Y, Anderson C, McEvoy D, Barbe F. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. JAMA. 2023 Oct 3;330(13):1255-1265. doi: 10.1001/jama.2023.17465.
- Hunt TE, Traaen GM, Aakeroy L, Bendz C, Overland B, Akre H, Steinshamn S, Loennechen JP, Hegbom F, Broch K, Lie OH, Lyseggen E, Haugaa KH, Gullestad L, Anfinsen OG. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: A randomized controlled trial. Heart Rhythm. 2022 Sep;19(9):1433-1441. doi: 10.1016/j.hrthm.2022.06.016. Epub 2022 Jun 16.
- Zhou Y, Yan M, Yuan J, Wang Y, Qiao S. Continuous Positive Airway Pressure Treatment Decreases the Risk of Atrial Fibrillation Recurrence in Patients with Obstructive Sleep Apnea after Radiofrequency Ablation. Int Heart J. 2022 Jul 30;63(4):716-721. doi: 10.1536/ihj.22-129. Epub 2022 Jul 14.
- Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ; ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015 May;169(5):647-654.e2. doi: 10.1016/j.ahj.2014.12.024. Epub 2015 Feb 7.
- Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med. 2018 Jun;46:5-11. doi: 10.1016/j.sleep.2018.02.013. Epub 2018 Mar 22.
- de Heide J, Kock-Cordeiro DBM, Bhagwandien RE, Hoogendijk MG, van der Meer KC, Wijchers SA, Szili-Torok T, Zijlstra F, Lenzen MJ, Yap SC. Impact of undiagnosed obstructive sleep apnea on atrial fibrillation recurrence following catheter ablation (OSA-AF study). Int J Cardiol Heart Vasc. 2022 Mar 24;40:101014. doi: 10.1016/j.ijcha.2022.101014. eCollection 2022 Jun.
- Minami T, Yoshizawa T, Murase K, Komasa A, Aizawa T, Yamagami S, Tanaka M, Shizuta S, Sato S, Ono K, Hirai T, Kimura T, Chin K. Associations Among Sleep Apnea, Objective or Subjective Sleep Duration, and Recurrence of Atrial Fibrillation in Patients Who Undergo Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation - A Prospective Observational Study. Circ J. 2025 Jan 24;89(2):184-194. doi: 10.1253/circj.CJ-24-0537. Epub 2024 Nov 12.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Maladies du système nerveux
- Maladies cardiovasculaires
- Les troubles mentaux
- Processus pathologiques
- Maladies cardiaques
- Maladies des voies respiratoires
- Troubles respiratoires
- Apnée
- Troubles du sommeil, intrinsèques
- Dyssomnies
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Fibrillation auriculaire
- Syndromes d'apnée du sommeil
- Apnée du sommeil, obstructive
- Troubles du sommeil et de l'éveil
- Arythmies cardiaques
- Thérapeutique
- Gestion des voies respiratoires
- Thérapie respiratoire
- Respiration à pression positive
- Respiration, artificiel
- Pression positive continue des voies respiratoires
Autres numéros d'identification d'étude
- KS2025046
- 2024ZD0529100 (Autre subvention/numéro de financement: Development Center for Medical Science & Technology National Health Commission of the People's Republic of China)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .